Answers are grounded in this paper and cite their sources.
Single-arm phase 2 trial evaluates treatment efficacy in advanced intrahepatic cholangiocarcinoma, indicating potential for future studies.
e16169 Background: Advanced intrahepatic cholangiocarcinoma (ICC) remains a highly aggressive malignancy with limited treatment options and poor prognosis. Systemic chemotherapy and immune therapies have shown modest efficacy, highlighting the need for novel combination strategies. This single-arm phase 2 study evaluated the efficacy and safety of tislelizumab (a PD-1 inhibitor) combined with apatinib (a VEGFR-2 inhibitor) and hepatic arterial infusion chemotherapy (HAIC) in patients with advanced ICC. Methods: Eligible patients with histologically confirmed advanced ICC were enrolled between Jan 2022 and Jun 2025. Treatment consisted of HAIC (oxaliplatin 130 mg/m²,5-Fu 400mg/ m², 5-Fu 1200mg/ m² via hepatic artery on day 1/2 each 3-week cycle), tislelizumab (200 mg intravenously every 3 weeks) and apatinib (250 mg orally daily). The primary endpoint was objective response rate (ORR) per RECIST v1.1, assessed by independent radiological review. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: A total of 17 patients were enrolled, with a median follow-up of 22 months. The confirmed ORR was 41.2% (95% CI: 18.4%-67.1%). The DCR was 88.3% (95% CI: 65.6%-98.5%). Median PFS was 8.8 months (95% CI: 4.33 - NA months), and the median OS was 17.6 months (95% CI: 15.0 - NA months). Notably, 3 of 17 patients (17.6%) subsequently underwent liver tumor resection with curative intent, achieving R0 resection. Eight patients (47.1%) had at least one any-grade treatment-related adverse event (TRAE); grade 3-4 TRAEs occurred in 3 patients (17.6%), with elevated transaminases (47.1%) being most common. No treatment-related deaths occurred. Conclusions: The combination of HAIC, tislelizumab and apatinib demonstrated promising efficacy with a manageable safety profile in advanced ICC, supporting further investigation in larger controlled trials.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: